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Abstract
Objective—Cytoreductive surgery for ovarian cancer has higher rates of postoperative 
complication than neoadjuvant chemotherapy followed by surgery. If patients at high risk of 
postoperative complication were identified preoperatively, primary therapy could be tailored. Our 
objective was to develop a predictive model to estimate the risk of major postoperative 
complication after primary cytoreductive surgery among elderly ovarian cancer patients.
Methods—Patients who underwent primary surgery for ovarian cancer between 2005-2013 were 
identified from the National Surgical Quality Improvement Project. Patients were selected using 
primary procedure CPT codes. Major complications were defined as grade 3 or higher 
complications on the validated Claviden-Dindo scale. Using logistic regression, we identified 
demographic and clinical characteristics predictive of postoperative complication.
Results—We identified 2,101 ovarian cancer patients of whom 35.9% were older than 65. 
Among women older than 65, the rate of major postoperative complication was 16.4%. 
Complications were directly associated with preoperative laboratory values (serum creatinine, 
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platelets, white blood cell count, hematocrit), ascites, white race, and smoking status, and 
indirectly associated with albumin. Our predictive model had an area under receiver operating 
characteristic curve of 0.725. In order to not deny patients necessary surgery, we chose a 50% 
population rate of postoperative complication which produced model sensitivity of 9.8% and 
specificity of 98%.
Discussion—Our predictive model uses easily and routinely obtained objective preoperative 
factors to estimate the risk of postoperative complication among elderly ovarian cancer patients. 
This information can be used to assess risk, manage postoperative expectations, and make 
decisions regarding initial treatment.
Introduction
Primary cytoreductive surgery to no gross residual disease is associated with improved 
survival among patients with ovarian cancer.(1) The extensive cytoreductive effort that is 
required to debulk advanced ovarian cancer to no gross residual disease can be associated 
with major postoperative complication rates as high as 50%.(2) The elderly are known to be 
at a particularly high risk of postoperative complication after cytoreductive surgery and 
these complications impact morbidity and mortality.(3) In a study by Moore et al of 
octogenarians, death prior to hospital discharge and within 60 days of surgery occurred in 
13% and 20% of cases, respectively and an additional 13% were unable to receive indicated 
postoperative therapy. The effects of postoperative complication can be farther-reaching 
than just morbidity and mortality related to surgery. Patients with postoperative 
complications experience delays in initiation of chemotherapy, may not be able to receive 
planned therapy, and experience subsequent decreased survival.(3, 4) Additionally, patients 
who receive neoadjuvant chemotherapy experience lower rates of postoperative 
complication compared to those who receive upfront cytoreductive surgery suggesting that 
neoadjuvant chemotherapy has the potential to decrease postoperative complications among 
patients at high risk.(2, 5)
Predictive models can provide a personalized assessment of the probability of a clinical 
event using patient specific characteristics and have increasingly been incorporated into the 
practice of oncology.(6, 7) Most oncologic predictive models require the input of 
demographic or disease specific variables and calculate the output of disease free or overall 
survival.(8, 9) In contrast, treatment-guiding predictive models can be helpful for clinical 
situations in which different options exist as treatment for a particular condition. In this 
scenario, outcomes from a predictive model give the user information that may influence 
their preference for a type of treatment. Ovarian cancer can be treated with either 
neoadjuvant chemotherapy or initial cytoreductive surgery making it particularly amenable 
to a predictive model.
Currently, neoadjuvant chemotherapy is the preferred therapy for ovarian cancer patients 
that have preoperatively identified unresectable disease, significant medical co-morbidities, 
or poor performance status. However, we do not currently have an accepted objective 
measure to determine which patients are least likely to benefit from an extensive 
cytoreductive effort. While many studies have focused on predicting the ability to resect 
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tumor to no gross residual disease, the patient's ability to tolerate surgery without significant 
morbidity is another important factor in triaging ovarian cancer patients for initial surgical 
management.(10, 11) If patients at high risk for postoperative complications could be 
identified preoperatively, patients and providers could use this information to personalize 
decisions regarding upfront surgical cytoreduction versus neoadjuvant chemotherapy.
Our objective was to create a novel predictive model to evaluate utility of readily available 
demographic and preoperative features to predict probability of postoperative complications 




Patients who underwent primary surgery for treatment of ovarian cancer from January 2005 
through December 2013 and were recorded in the American College of Surgeons National 
Surgical Quality Improvement Program (ACS-NSQIP) were included in this study. Patients 
were identified from the database for inclusion using the primary procedure Current 
Procedure Terminology (CPT) code. Only procedures with CPT codes that are specific to 
the initial treatment of ovarian cancer were included (58950, 58951, 58952, 58953, and 
58954). The Institutional Review Board of the University of North Carolina at Chapel Hill 
reviewed this study and declared it exempt from formal review as it does not constitute 
human subjects research.
NSQIP is a national surgical quality program that provides risk-adjusted outcome measures 
for participating institutions to measure and improve the quality of care they deliver. Each 
entry in the database is an individual surgical procedure and includes variables associated 
with that surgical procedure. Specially trained nurses prospectively enter surgical case 
variables such as patient demographics, preoperative variables, intraoperative variables, and 
postoperative variables. Data is collected for the 30 days following surgery. The data is then 
de-identified of patient, hospital, and location-specific information and placed into the 
NSQIP database.(12)
Measures
The outcome of interest, major postoperative complication, was a binary composite outcome 
and included all grade 3, 4 or 5 complications on the validated Clavien-Dindo scale(13) that 
are recorded in the NSQIP database. Major postoperative complications included myocardial 
infarction, pneumonia, venous thromboembolism, deep surgical site infection, stroke with 
neurologic deficit, unscheduled return to the operating room, renal failure, cardiopulmonary 
arrest, sepsis, intubation greater than 48 hours, or death. All outcomes were evaluated for 30 
days postoperatively. More specific definitions of the criteria used to define each specific 
postoperative complication can found in the NSQIP data participant use file.(12) Only grade 
3 complications and higher were included as these are complications that are sufficiently 
grave that patients and providers may alter plans for type of initial treatment if they had 
preoperative knowledge that these outcomes were likely.
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Potential predictors of major complications were identified based on the current literature 
that suggests that certain preoperative characteristics are associated with postoperative 
complication. In addition, predictors had to be easy to assess preoperatively and objective in 
order to decrease intra-observer variability, subjectivity, and increase ease of use in the 
clinical setting. Objective numerical variables such as laboratory values or categorical 
variables with little intra-observer variability were preferentially included. Variables such as 
American Society of Anesthesiologist (ASA) scores, which are likely associated with 
complications, were not included as they require the user to determine the ASA score 
preoperatively which hinders the ease of use of the score. Both age and BMI have been 
associated with complications among gynecologic oncology patients(11, 14). Low albumin, 
low hematocrit, elevated creatinine, and thrombocytopenia are associated with poor 
performance status and have been associated with complications among a diversity of 
surgical patients(15-21). In regard to cancer biology, both white blood cells and platelets 
have been linked to aggressive cancer biology, poor prognosis, and postoperative 
complications among ovarian cancer patients(22-25). The predictors of major complication 
that we investigated included patient demographics, including age and race; preoperative 
laboratory values, including platelet count, white blood cell count, creatinine, albumin, and 
hematocrit; and patient comorbidities, including diabetes, hypertension, chronic obstructive 
pulmonary disease (COPD), myocardial infarction (MI) within 6 months, history of 
cerebrovascular accident (CVA) and history of transient ischemic attack (TIA). These 
comorbidities were defined as per the NSQIP user guide.(26)
Statistical Analyses
We developed a predictive model using multiple logistic regression restricted to persons in 
the dataset greater than 65 years of age. This elderly-focused analysis was driven by 
previous studies that have found a direct relationship between age and postoperative 
complications and mortality in ovarian cancer patients undergoing cytoreductive surgery and 
that patients receiving neoadjuvant chemotherapy are older than those receiving primary 
debulking surgery (11, 27-30). Additionally, the predictors of major complication may be 
different between young and old patients and the median age at ovarian cancer diagnosis is 
63 years of age. Thus, we decided to examine the subset of our population that would be 
more likely to receive neoadjuvant chemotherapy and more likely to have a postoperative 
complication. We first conducted bivariate analyses with predictor variables hypothesized to 
be associated with major postoperative complication. We used Akaike's information criteria 
(AIC) to identify appropriate functional form for each variable(31), testing linear, quadratic, 
categorical, binary, and in some cases restricted quadratic splines according to the observed 
distribution of the predictor variable.
The model was composed of a priori identified demographics and preoperative clinical 
variables with bivariate p-values <0.5. This high threshold was chosen to ensure that 
available important predictors were not excluded.(32) Investigated variables that did not 
meet this bivariate p-value threshold of p<0.5 were not included in the predictive model.
All variables were included based on hypothesized associations that were confirmed in 
bivariable analyses. The anticipated implementation of this risk score is the creation of a tool 
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by which clinicians could input the predictors into a computer program that would calculate 
the predicted probability of a major postoperative complication. Therefore, there is no cost 
to the inclusion of all of the predictor variables and we did not reduce the model with 
backwards elimination after variables were identified as appropriate for inclusion based on 
bivariable analyses.
We assessed the area under the receiver operating characteristic curves (AUROC) for each 
model (chi-squared test).(33) AUROC is a measure of an algorithm's discriminatory power –
where 1.0 indicates a perfect test (i.e., 100% sensitivity and 100% specificity).(34) Model 
calibration was assessed using Hosmer-Lemeshow (HL) goodness-of-fit tests.(35) All 




We identified 2,101 patients who underwent primary surgery for the treatment of ovarian 
cancer and 35.9% (n=751) were older than 65 years old. These 751 women comprised our 
study population. Demographic and preoperative characteristics for all patients as well as 
only those greater than 65 years old are listed in Table 1 for comparison purposes. The rate 
of major complication was 12.3% for the full population and 16.4% among women older 
than 65 years old.
Bivariable analyses
We compared elderly patients with major complication to those without to determine 
associations with demographic or preoperative variables. Patients older than 65 years old 
who experienced a major complication were more likely to have ascites (p<0.0001) 
compared to those without a major complication. They also had lower preoperative albumin 
(p<0.0001) as well has higher preoperative white blood cell counts (p=0.009) and serum 
creatinine levels (p=0.003) (Table 2).
Multivariable analyses
Investigated variables associated with major postoperative complication in bivariable 
analysis with a p-value<0.5 were included in the predictive model and included preoperative 
creatinine, preoperative platelet count, preoperative hematocrit, preoperative white blood 
cell count, preoperative albumin, ascites, smoking status, and a binary indicator of race 
(white vs non-white) (Table 3). Investigated variables that did not meet the criteria of p<0.5 
and thus were not included in the predictive model included age, BMI, hypertension, 
diabetes, COPD, MI, CVA, and TIA. Predictors associated with major complication on 
bivariable analysis were then placed in a multivariable logistic regression model to evaluate 
predictors associated with the outcome of major complication (Supplementary Table 1). The 
full model included 8 predictor variables (AUROC=0.725) (Figure 1). The HL calibration 
test failed to reject the null hypothesis that there was a statistically significant difference 
between observed and predicted estimates (p=0.53) meaning that the predicted and observed 
estimate are similar and the model is predictive.
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Another way to evaluate the performance of this algorithm is examination of the algorithm's 
sensitivity and specificity at various clinically-relevant thresholds. In this scenario, the 
outcome (predicted probability of major complication) is treated as a binary event rather 
than a probability or percentage. For example, for patients with a 35% predicted probability 
of experiencing a complication, our algorithm is 21.8% sensitive and 92.6% specific. Put 
another way, using a threshold of 35% probability of complication, we would capture 
approximately 20% of the total population of women who will experience a complication. 
At a threshold of 50% probability of experiencing a major complication, the sensitivity 
drops to 9.8%, so only capturing approximately 10% of women who will experience this 
outcome, but specificity is 98.0%. Thus, we accurately classify the vast majority of women 
who will not experience a complication.
We set the rate of major postoperative complication at a rate that is reflected in the current 
literature, which varies between 9% and 52.6%.(2, 5, 36, 37) Given this large range, we 
elected to use a higher rate of postoperative complication as we did not want the model 
output to prevent patients from obtaining surgery who would otherwise benefit from it. Put 
another way, we desired a high specificity for our model and only wanted to predict 
postoperative complication for patients who were highly likely to experience one. This is 
because when the model is used in clinical practice, we want the plan for upfront 
cytoreductive surgery to only be altered if the probability of a major postoperative 
complication and resulting morbidity and mortality is high.
Discussion
We have developed a predictive model using standard and readily available objective 
preoperative factors to predict major postoperative complication among elderly ovarian 
cancer patients. This model can be used as a risk assessment tool, similar to the Gail model 
for breast cancer, in which the clinician and/or patient input the preoperative factors and the 
model output is displayed as a probability that the specific patient experiences a 
postoperative complication. All model inputs are empirical and straightforward to assess 
preoperatively, in fact, most are objective numbers such as laboratory values.
Prior studies have identified factors that are associated with postoperative complication 
among ovarian cancer patients. Studies have found that older age, poor nutrition status, and 
stage IV disease are associated with postoperative complication.(3, 11, 38) A recent study 
using NSQIP data to examine ovarian cancer patients found that greater than three extended 
procedures is a stronger risk factor for postoperative complication than demographic or 
clinical factors.(39) Our study differs from this study in a number of ways. Our goal was to 
develop a predictive model that can be used as a pre-operative tool by clinicians and patients 
and that drove our methodology. This led us to select a higher risk population by including 
only patients greater than 65 years of age as this is the population that gynecologic 
oncologists most often consider neoadjuvant chemotherapy in. We also only included 
variables that are known preoperatively in our model, as although the number of surgical 
procedures performed at the time of cytoreductive effort maybe an important risk factor, the 
true number of procedures required will not be known until the time of surgery at which 
point the information can no longer be used to make decisions regarding initial treatment.
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In order to best select the subgroup of patients that will benefit from upfront cytoreductive 
surgery versus neoadjuvant chemotherapy, much attention has been focused on developing 
predictive models to assess which patients will be able to be cytoreduced to no gross 
residual disease. Models using CA125, CT scans, and laparoscopy have all been employed.
(10, 40-42) All of these models have one thing in common: the desire to transform 
something potentially subjective to an objective measurable score. While the ability to 
achieve resection to no gross residual disease is an important factor in selecting primary 
treatment for ovarian cancer, the patient's likelihood of experiencing a major postoperative 
complication is another important factor. Patients who experience major complications 
experience morbidity and mortality related to their complications, reductions in quality of 
life, and chemotherapy delays, which can result in compromised survival.(3, 4) Aletti et al 
performed a multicenter study, which found a subgroup of patients with older age, poor 
performance or nutritional status, and disseminated disease among whom the benefits of 
extensive surgical efforts do not outweigh the risks.(11) These patients had a 63.6% risk of 
postoperative morbidity and a decreased survival (17 months versus 27 months) associated 
with extensive cytoreductive efforts. Currently, in clinical practice, a combination of patient 
comorbidities, age, and functional status are used to decide between neoadjuvant 
chemotherapy and upfront cytoreductive surgery, however, much of this is subjective. Just 
as the aforementioned cytoreductive scores inject objectivity into the question of whether 
optimal cytoreductive surgery can be performed, our predictive model allows surgeons to 
use easily obtained preoperative data to objectively assess the possibility of a postoperative 
complication and resulting morbidity.
Our predictive model can be used in two ways – either as a quantitative model which 
displays the output of major complication as a probability for the individual patient or as a 
predictor of a binary event, that the patient experiences or does not experience a major 
complication. In the quantitative model, the model output is the risk or continuous 
probability that the patient experiences a major complication. Our quantitative model has 
reasonable discriminatory power with an AUROC of 0.725.
When the model is used to predict a binary outcome, we classify the postoperative 
complication outcome as a binary event, rather than a continuous probability. In this version, 
the specificity is high at 98%, meaning that we will accurately identify 98% of patients who 
will not experience a postoperative complication. The high specificity of the model is 
particularly useful clinically. It means that upfront cytoreductive surgery is the standard for 
all patients whom a physician would normally operate on and that the predictive model only 
indicates that a patient will experience a postoperative complication if that outcome is highly 
likely. For example, when used in clinical practice, the user would input the model 
predictors and a postoperative major complication would be either predicted or not 
predicted. If a major complication is not predicted, surgery can proceed, as the probability of 
a major complication is very low (specificity of 98%). If a major complication is predicted, 
the patient and provider should assess comorbidities, the likelihood of achieving optimal 
cytoreduction and determine if the risk of oncologic benefit outweighs the risk of 
postoperative morbidity. In this scenario, the quantitative model may be helpful to quantitate 
the risk of postoperative morbidity and guide decision-making.
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Our predictive model uses the inputs of preoperative serum creatinine, platelet count, 
preoperative hematocrit, white blood cell count, albumin, as well as ascites, current 
smoking, and race to estimate the probability that a specific patient experiences a 
postoperative complication. Increasingly in medicine we are moving towards individualized 
medicine where care is tailored to fit the patient. Quality and reproducibility in medical care 
have also gained increasing prominence. Currently, we have no accepted method for 
quantifying surgical risk in patients undergoing surgery for ovarian cancer and so there is 
great variation in physician practice patterns. By providing patients and their surgeons with 
a patient-specific quantitative risk probability, this calculator could help to both 
individualize and standardize the initial treatment of ovarian cancer.
Patient autonomy and quality of life are important for patients. Increasing attention has been 
paid to patient preferences with the accepted concept that it is not just quantity of life but the 
quality of life that is important to patients. This concept is especially important in the 
geriatric oncology population as these patients often present with “multimorbidity”. Multi-
morbidity is the concept that older patients often present with multiple overlapping chronic 
conditions and that a practical and rationale approach must be taken to treating these patients 
as clinical practice guidelines are often not tailored to these complicated patients.(43) If 
elderly patients were provided with the output of our model and therefore an individualized 
assessment of the likelihood that they would experience a major complication after surgery 
for ovarian cancer it would enhance their ability to participate in shared decision-making 
regarding their initial treatment. We know that postoperative complications are associated 
with longer hospitalizations and decreased quality of life. Patients armed with the 
information that they are at high risk of a major complication might decide to defer initial 
surgical management in favor of neoadjuvant chemotherapy.
Limitations of our study include those that pertain to the use of a large national quality 
database. Data on cancer specific variables are missing from the NSQIP database and so we 
cannot use stage or CA125 levels in our models for postoperative complication. 
Additionally, selection of patients was based on CPT codes and we cannot exclude the 
possibility of miscoding or misclassification. However, in contrast to large databases, which 
utilize billing and coding data only, the NSQIP database is prospectively collected by 
trained personnel for the purpose of surgical quality and perioperative complication 
measurement.(12) NSQIP only records post-operative data for 30 days after surgery and thus 
our complication rates do not include events, which occurred after that time point and 
therefore we may have underestimated the true risk of postoperative complication. 
Additionally, by definition, the NSQIP database only included patients who underwent 
surgery for the treatment of ovarian cancer and have therefore been deemed fit enough by a 
surgeon to enter the operating room. Some of the same factors that we use in our risk 
calculator such as age and other markers of medical comorbidity may have been used by the 
surgeons in this study preoperatively to make a decision not to operate and thus the true rate 
of postoperative complication in an unselected population may actually be higher. The high 
rate of postoperative complication that we selected in our binary output model minimizes 
these limitations. Lastly, this predictive model was specifically developed in a cohort of 
elderly ovarian cancer patients and cannot be extrapolated to predict complications among 
patients less than 65 years old.
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We have developed a predictive model to estimate the risk of postoperative complication 
among elderly patients undergoing primary surgery for the treatment of ovarian cancer 
based on easily obtained objective preoperatively-known factors. Postoperative complication 
is associated with morbidity, decreased quality of life, delay in receipt of chemotherapy, and 
mortality. The information from this model can be used by patients and providers to help 
them assess risk, manage postoperative expectations, and make decisions regarding initial 
treatment.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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• A preoperative risk assessment tool predicts major postoperative complication 
among elderly ovarian cancer patients undergoing cytoreductive surgery.
• This risk assessment tool can be used by clinicians and patients to help make 
decisions regarding initial ovarian cancer treatment.
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Figure 1. Area Under the Receiver Operator Curve (AUROC) for Regression Model
The area under an ROC curve is a measure of model performance. Specifically, the area 
measures discrimination – in this case the ability of the predictive model to correctly classify 
persons with and without postoperative complication. The observed AUROC for this model 
was 0.725.
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Table 1
Population Characteristics
Overall (n=2,101) Women >65yo (n=751, 35.7%)
Age (years)
 ≤ 65 1343 (63.9) 0 (0.0)
 66 – 70 292 (13.9) 292 (38.9)
 71 – 80 352 (16.8) 352 (46.9)
 81 - 90 107 (5.1) 107 (14.2)
BMI (kg/m2)
 < 18.5 48 (2.3) 17 (2.3)
 18.5 – 24.9 645 (30.7) 262 (34.9)
 25 – 29.9 581 (27.7) 242 (32.2)
 30 – 34.9 392 (18.7) 133 (17.7)
 35 – 39.9 218 (10.4) 55 (7.3)
 ≥ 40 190 (9.0) 36 (4.8)
 Unknown 21 (1.6%) 6 (0.8%)
Race
 White 1563 (74.4) 590 (78.6)
 Black 194 (9.2) 52 (6.9)
 Asian 91 (4.3) 25 (3.3)
 Unknown 253 (12.1) 84 (11.2)
Hypertension requiring medication
 Yes 901 (42.9) 454 (60.5)
 No 1200 (57.1%) 297 (39.5)
Smoker
 Yes 319 (15.2) 61 (8.1)
 No 1782 (84.8) 690 (91.9)
Insulin-Dependent Diabetes
 Yes 247 (11.8) 99 (13.2)
 No 1854 (88.2) 652 (86.8)
History of severe COPD
 Yes 58 (2.8) 36 (4.8)
 No 2043 (97.2) 258 (95.2)
History of CVA
 Yes 6 (0.3) 3 (0.4)
 No 2095 (99.7) 748 (99.6)
MI within 6 months
 Yes 2 (0.1) 1 (0.1)
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Overall (n=2,101) Women >65yo (n=751, 35.7%)
 No 2099 (99.9) 750 (99.9)
History of TIA
 Yes 12 (0.6) 11 (1.5)
 No 2089 (99.4) 740 (98.5)
Preoperative creatinine (mg/dL)
 < 1.5 1869 (89.0) 681 (90.7)
 ≥ 1.5 61 (2.9) 34 (4.5)
 Unknown 171 (8.1) 36 (4.8)
Preoperative hematocrit (%)
 < 30 163 (7.8) 67 (8.9)
 ≥ 30 1853 (88.2) 664 (88.4)
 Unknown 85 (4.0) 20 (2.7)
Preoperative platelet count (10̂9/L)
 < 450
 ≥ 450 1823 (86.8) 666 (88.7)
 Unknown 199 (9.5) 66 (8.8)
79 (3.8) 19 (2.5)
Preoperative white blood cell count (10̂9/L)
 < 10 1628 (77.5) 606 (80.7)
 ≥ 10 393 (18.7) 123 (16.4)
 Unknown 80 (3.8) 22 (2.9)
Preoperative albumin (g/dL)
 < 3.5 345 (16.4) 153 (20.4)
 ≥ 3.5 1079 (51.4) 391 (52.1)
 Unknown 677 (32.3) 207 (27.6)
Ascites
 Yes 407 (19.4) 164 (21.8)
 No 1694 (80.6) 587 (78.2)
Data is reported as n(%). BMI (body mass index), chronic obstructive pulmonary disease (COPD), myocardial infarction (MI), cerebrovascular 
accident (CVA), and transient ischemic attack (TIA). Bolded text indicates statistical significance with p<0.05.
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Table 2
Bivariable Associations for Elderly Women (> 65 years-old)
No major complication (n=628, 83.6%) Major complication (n=123, 16.4%) p value
Age (years) 0.58
 >65 – 70 244 (38.9) 48 (39.0)
 71 – 80 298 (47.5) 54 (43.9)
 81 - 90 86 (13.7) 21 (17.1)
BMI (kg/m2) 0.63
 < 18.5 14 (2.2) 3 (2.5)
 18.5 – 24.9 224 (35.9) 38 (31.4)
 25 – 29.9 206 (33.0) 36 (29.8)
 30 – 34.9 109 (17.5) 24 (19.8)
 35 – 39.9 43 (6.9) 12 (9.9)
 ≥ 40 28 (4.5) 8 (6.6)
Race 0.25
 White 489 (77.9) 101 (82.1)
 Black 41 (6.5) 11 (8.9)
 Asian 24 (3.8) 1 (0.8)
 Unknown 74 (11.7) 10 (8.1)
Hypertension requiring medication 0.78
 Yes 381 (60.7) 73 (59.3)
 No 247 (39.3) 50 (40.7)
Smoker 0.28
 Yes 48 (7.6) 13 (10.6)
 No 580 (92.4) 110 (89.4)
Insulin-Dependent Diabetes 0.60
 Yes 81 (12.9) 18 (14.6)
 No 547 (87.1) 105 (85.4)
History of severe COPD 0.64
 Yes 29 (4.6) 7 (5.7)
 No 599 (95.4) 116 (94.3)
History of CVA 1.0
 Yes 3 (0.5) 0 (0.0)
 No 625 (99.5) 123 (100.0)
MI within 6 months 1.0
 Yes 1 (0.2) 0 (0.0)
 No 627 (99.8) 123 (100.0)
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No major complication (n=628, 83.6%) Major complication (n=123, 16.4%) p value
History of TIA 0.70
 Yes 9 (1.4) 2 (1.6)
 No 619 (98.6) 121 (98.4)
Preoperative creatinine (mg/dL) 0.003
 < 1.5 574 (96.3) 107 (89.9)
 ≥ 1.5 22 (3.7) 12 (10.1)
Preoperative hematocrit (%) 0.098
 < 30 51 (8.4) 16 (13.1)
 ≥ 30 558 (91.6) 106 (86.9)
Preoperative platelet count (10̂9/L) 0.166
 < 450 559 (91.9) 107 (87.7)
 ≥ 450 51 (8.4) 15 (12.3)
Preoperative white blood cell count (10̂9/L) 0.009
 < 10 516 (84.7) 90 (75.0)
 ≥ 10 93 (15.3) 30 (25.0)
Preoperative albumin (g/dL) <0.0001
 < 3.5 101 (22.7) 52 (52.5)
 ≥ 3.5 344 (77.3) 47 (47.5)
Ascites <0.0001
 Yes 119 (18.9) 45 (36.6)
 No 509 (81.1) 78 (63.4)
Data is reported as n(%). BMI (body mass index), chronic obstructive pulmonary disease (COPD), myocardial infarction (MI), cerebrovascular 
accident (CVA), and transient ischemic attack (TIA). Bolded text indicates statistical significance with p<0.05.
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Table 3
Unadjusted and Adjusted Multivariable Model for Postoperative Complication among 
Elderly Patients
Predictor Unadjusted Prevalence OR Adjusted Prevalence OR
OR (95% CI) OR (95% CI)
Preoperative creatinine 1.2 (1.0-1.6) 1.3 (0.8-2.2)
Preoperative platelet
 >450 1.5 (0.8-2.8) 0.8 (0.4-1.8)
 ≤450 1.0
Preoperative hematocrit 0.9 (0.9-1.0) 1.1 (0.7-1.8)1
Preoperative white blood cell 1.1 (1.0-1.1) 1.1 (1.0-1.1)
Preoperative albumin 0.3 (0.2-0.5) 0.4 (0.2-0.6)
Ascites
 Yes 2.5 (1.7-3.8) 1.7 (1.0-2.9)
 No 1.0
Current smoker
 Yes 1.1 (0.8-1.6) 1.2 (0.5-2.8)
 No 1.0
Race
 White 1.3 (0.8-2.2) 1.2 (0.6-2.2)
 Non-white 1.0
1
For a 10-unit change in Hct
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